A Prospective, Randomized, Double-Blinded, Multi-Center Trial Assessing the Safety and Efficacy of Intravenous Administration BAY12-8039 (Moxifloxacin) 400mg Every 24 h Compared to Intravenous Ceftriaxone 2g Every 24h and Metronidaxole 500mg Every 12h for the Treatment of Patients With Complicated Intra-Abdominal Infections.

Trial Profile

A Prospective, Randomized, Double-Blinded, Multi-Center Trial Assessing the Safety and Efficacy of Intravenous Administration BAY12-8039 (Moxifloxacin) 400mg Every 24 h Compared to Intravenous Ceftriaxone 2g Every 24h and Metronidaxole 500mg Every 12h for the Treatment of Patients With Complicated Intra-Abdominal Infections.

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Dec 2014

At a glance

  • Drugs Moxifloxacin (Primary) ; Ceftriaxone; Metronidazole
  • Indications Bacteroides infections; Escherichia coli infections; Intra-abdominal infections
  • Focus Therapeutic Use
  • Acronyms DRAGON
  • Sponsors Bayer
  • Most Recent Events

    • 01 Nov 2009 Primary endpoint 'Clinical success rate' has been met.
    • 01 Nov 2009 Results published in the International Journal of Antimicrobial Agents.
    • 23 Oct 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top